Navigation Links
Transcept Pharmaceuticals Reports Third Quarter 2009 Financial Results
Date:11/12/2009

September 30, 2008.

Research and development expense for the nine months ended September 30, 2009 was approximately $6.61 million, compared to approximately $8.84 million for the same period in 2008. The $2.23 million decrease is primarily attributable to lower Intermezzo® development costs, the majority of which were incurred prior to the submission of the Intermezzo® NDA on September 30, 2008. Research and development expense included non-cash stock compensation expense in accordance with ASC Topic 718 of approximately $391,000 for the nine months ended September 30, 2009 and approximately $192,000 for the nine months ended September 30, 2008.

General and administrative expense for the nine months ended September 30, 2009 was approximately $13.07 million, compared to approximately $5.37 million for the same period in 2008. The $7.70 million increase consists primarily of higher professional fees to operate as a public company and to negotiate our collaboration with Purdue, increased personnel costs primarily in marketing and administration, increased marketing expense as we prepared to commercialize Intermezzo® and an increase in operational expenses associated with additional office space. General and administrative expense included non-cash stock compensation expense in accordance with ASC Topic 718 of approximately $693,000 for the nine months ended September 30, 2009, as compared to approximately $268,000 for the nine months ended September 30, 2008.

Year-to-date merger-related transaction costs of approximately $2.22 million were expensed during the first quarter of 2009.

Net loss for the nine months ended September 30, 2009 was approximately $19.5 million or $1.65 per share, compared to a net loss of approximately $13.8 million or $35.93 per share for the nine months ended September 30, 2008. The weighted average shares used to calculate net loss per share were 11,764,
'/>"/>

SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Transcept Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference on November 17
2. Transcept Pharmaceuticals to Report Third Quarter 2009 Results and Host Conference Call on November 12
3. Transcept Pharmaceuticals Receives Complete Response Letter from FDA on Intermezzo(R) New Drug Application
4. Transcept Pharmaceuticals to Report First Quarter 2009 Results
5. Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings
6. Transcept Pharmaceuticals Announces Intent to Submit New Drug Application for Intermezzo(R) in Third Quarter 2008
7. Biostar Pharmaceuticals, Inc. Announces Record Third Quarter 2009 Financial Results
8. Onyx Pharmaceuticals to Present at the Lazard Capital Markets 6th Annual Healthcare Conference
9. Webcast Alert: Isis Pharmaceuticals and Genzyme Corporation to Present Mipomersen Phase 3 Data in HoFH During AHA
10. Endo Pharmaceuticals and LecTec Settle Patent Dispute
11. Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 (Perifosine) at the 51st Annual Meeting of the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... DIEGO , July 11, 2014 Neurelis, ... Corp. ("Biotie") to end the option held by Biotie ... commence further development of NRL-1 (intranasal diazepam) for pediatric ... Over the past year, Biotie has advanced ... in preparation for the pivotal clinical work required for ...
(Date:7/10/2014)... 2014  Breg, Inc., a premier provider of ... FreeRunner™ knee brace with new innovations to help ... return to active lifestyles.  FreeRunner,s patent-pending design acts ... support when patients need it most, and the ... Patellofemoral issues are the most common cause ...
(Date:7/10/2014)... 10, 2014  BC Technical, the largest nationwide, non-OEM ... , Inc., a leading provider of Siemens Nuclear Medicine ... agreement naming BC Technical as the authorized provider of ... MiE and BC Technical announced today that the two ... Technical as the service and systems provider for MiE,s ...
Breaking Medicine Technology:Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2
... Calif., June 2, 2011 DURECT Corporation (Nasdaq: ... Chief Medical Officer and Executive Vice President, Corporate Strategy ... opportunities.  Dr. Stauffer and DURECT have entered into a ... (Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO ) "We appreciate all ...
... SAN DIEGO, June 2, 2011 Biocept, Inc. today ... a poster at the 2011 Annual Meeting of the ... Chicago, Illinois June 3-7. The poster presentation is based ... logy C ell E nrichment and ...
Cached Medicine Technology:DURECT Announces Resignation of Chief Medical Officer 2Biocept and Academic Collaborators to Present Poster at ASCO on Circulating Tumor Cells (CTCs) 2Biocept and Academic Collaborators to Present Poster at ASCO on Circulating Tumor Cells (CTCs) 3
(Date:7/11/2014)... 2014 The Europe Well Intervention Market report ... with analysis and revenue forecast. The well intervention services market ... in 2013 to $3.4 billion by 2018, at a CAGR ... TOC of the Europe Well Intervention Market report, to get ... a glimpse of the segmentation in the Europe well intervention ...
(Date:7/11/2014)... 11, 2014 Operators and ... billion in fuel costs now that model ... current GHG standards are phasing in ... upon themselves to install new features into ... reduction technologies , 2.    Efficient driveline components which ...
(Date:7/11/2014)... (HealthDay News) -- U.S. health officials have concluded that ... live anthrax during a safety mishap last month. ... officials have announced a moratorium on the transfer of ... In a report issued Friday, the CDC outlined ... a similar incident doesn,t occur again. Last month, as ...
(Date:7/11/2014)... CT (PRWEB) July 11, 2014 ... the nation’s only non-profit dedicated exclusively to cell ... that Joshua Corday has joined the organization as ... fundraising professional with deep experience securing gifts and ... served as Annual Giving Director for NewYork Presbyterian ...
(Date:7/11/2014)... July 11, 2014 Biostimulants are widely ... in turf and ornamentals. These also help turf and ... length of roots. Turf, ornamentals, and flowers appear healthy ... this usage has increased from the last few years. ... and ornamentals is Europe, with around 40% share in ...
Breaking Medicine News(10 mins):Health News:Europe Well Intervention Services Market is Expected to Reach $3.4 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:Europe Well Intervention Services Market is Expected to Reach $3.4 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 2Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 3Health News:CDC Issues Tough Report on Anthrax Scare 2Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 2Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 3Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 3
... 6 percent of U.S. hospital emergency departments are fully ... of novel H1N1 (swine) flu expected this winter, the ... In a joint policy statement published in Pediatrics ... Department," pediatric emergency medicine specialists and others provide recommendations ...
... Federal stimulus funding is helping a Kansas State University ... Their research is creating a clearer picture of a ... chronic diseases like cancer. Katsura Asano, K-State associate ... from the National Institutes of Health,s National Institute of ...
... so-called junk DNA to be cut and pasted within genetic ... therapies. The study by researchers at the University of ... in which shifted genes have a significant effect on the ... antibody genes can enable the immune system to target infection ...
... NEW YORK, Sept. 21 Within the first three seconds ... in many first encounters, from the first day of school to the ... help you exude confidence, so follow these helpful tips to get yourself ... go to: http://www.prnewswire.com/mnr/crest/39172/ , , ...
... INDIANAPOLIS, Sept. 21 Eli Lilly and Company ... on the Human Rights Campaign,s (HRC) Corporate Equality Index for 2010. ... the Best Places to Work for Lesbian, Gay, Bisexual, and Transgender (LGBT) ... organization,s efforts related to creating an equitable environment for lesbian, gay, bisexual, ...
... , , ABBOTT PARK, Ill., Sept. 21 ... from the U.S. Food and Drug Administration (FDA) for its ABBOTT PRISM ... HIV-1/HIV-2. This test can be used by laboratory professionals to screen ... type 1 Groups M and O (anti-HIV-1) and type 2 (anti-HIV-2), and ...
Cached Medicine News:Health News:Photos: Fall's First Impressions 2Health News:Lilly Receives 100 Percent Rating on Corporate Equality Index Survey 2Health News:Abbott Receives FDA Approval for First Fully Automated Blood Screening Test for HIV-1/HIV-2 2Health News:Abbott Receives FDA Approval for First Fully Automated Blood Screening Test for HIV-1/HIV-2 3
... In the specialty areas of ... intensive care work, it is ... your practice. Alokas motorized TEE ... and Tissue Harmonic Echo technology ...
Super High Density, multi-frequency, convex array transducer for scanning during craniotomies. Same footprint as the UST-987-7.5 but with stronger penetration for deep cavernous tumors and other deep...
... The 5548 is our High Penetration ... frequencies ranging from 3 to 8 MHz. ... transducer, offering Pure Harmonic Detection with 4 ... superficial or deeper vessels. The high color ...
... The UST-MC11-8731 is a perfect alternative ... are used to seeing more of a ... of the transducer in the hand., This ... shaped convex intraoperative transducer. The UST-MC11-8731 nestles ...
Medicine Products: